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Vaccination can play a central role in the control of outbreaks of foot-and-mouth disease 
(FMD) by reducing both the impact of clinical disease and the extent of virus transmis-
sion between susceptible animals. Recent incursions of exotic FMD virus lineages into 
several East Asian countries have highlighted the difficulties of generating and main-
taining an adequate immune response in vaccinated pigs. Factors that impact vaccine 
performance include (i) the potency, antigenic payload, and formulation of a vaccine; 
(ii) the antigenic match between the vaccine and the heterologous circulating field strain; 
and (iii) the regime (timing, frequency, and herd-level coverage) used to administer the 
vaccine. This review collates data from studies that have evaluated the performance of 
foot-and-mouth disease virus vaccines at the individual and population level in pigs and 
identifies research priorities that could provide new insights to improve vaccination in the 
future.
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iNTRODUCTiON
Foot-and-mouth disease (FMD) is a viral disease of cloven-hooved animals causing severe economic 
impacts (1). The disease circulates widely in sub-Saharan Africa and Asia, but has been largely eradi-
cated from South America as well as much of the developed world. It is caused by a Picornavirus 
(FMD virus: FMDV) that exists as seven immunologically distinct serotypes. Global FMD control 
efforts are focused at reducing the burden of disease, with the longer-term goal to sequentially elimi-
nate the virus from livestock populations. Vaccination can be a highly effective tool to control FMD, 
especially when it is implemented together with effective zoo-sanitary measures (farm biosecurity 
and quarantine) and culling of infected animals. During the 1980s, vaccines were used to effectively 
eradicate FMD from continental Europe (2), and, more recently, FMD control in South America has 
employed extensive use of vaccination (3).
In attempts to maximize the impact of limited vaccine resources, most FMD control programs 
emphasize the use of FMDV vaccines in cattle. As a consequence, many of the published studies that 
evaluate FMDV vaccine performance have also focused exclusively on their use in cattle. However, 
some countries have large pig populations that are a major target for FMDV vaccination. The impact 
of FMD in pigs has recently become particularly important in many Asian countries, such as China 
FiGURe 1 | Schematic representation of the reasons for a failure in vaccination divided into “vaccine failure” and “failure to vaccinate.” Adapted from 
Ref. (13).
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and the Republic of Korea, where there have been extensive and 
sustained FMD outbreaks due to serotype O and A lineages that 
have emerged from mainland Southeast Asia (4, 5). The contin-
ued occurrence of FMD cases in countries that have large pig 
populations despite extensive vaccination has raised questions 
about the effectiveness of vaccination in pigs, but published field 
studies that analyze this issue appear to be lacking. This review 
highlights the difficulties of FMDV vaccination in pigs at the indi-
vidual and population level and summarizes the studies that have 
evaluated the performance of FMDV vaccines in this important 
domesticated livestock species.
GeNeRAL CONSiDeRATiONS FOR FMD 
vACCiNATiON
Types of vaccines in Commercial Use 
Today in Pigs
Foot-and-mouth disease vaccines have been produced on a large 
scale since the 1940s (6) and are currently manufactured by at 
least 56 commercial and governmental institutions around the 
world (O Mezzer, Vallée SA, Personal Communication, 2014). In 
all FMDV susceptible species, there are many types of vaccine 
available, not just by virtue of the serotypes and strains included, 
but also the adjuvant (aluminum hydroxide/saponin or oil adju-
vants as: oil in water, water in oil, and double water emulsion) 
and inactivation method (binary ethyleneimine or rarely formal-
dehyde) (7). For pigs, currently available vaccines are formulated 
with an oil adjuvant, due to poor immunogenicity with the aque-
ous equivalents, and contain either killed/inactivated FMD virus 
or a synthetic viral peptide (8, 9).
Reasons for vaccine Failure
There are a number of problems with current FMD vaccines that 
limit their effective use. These include: imperfect antigenic match 
between the field virus and vaccine strain; variable antigenic 
payload; antigen instability (principally the 146S virus particles); 
requirement for a cold-chain; poor adaptation of certain strains 
for vaccine production; short duration of protection and require-
ments for repeat boosting; non-sterile immunity with clinically 
protected animals sometimes becoming infected; high levels of 
coverage required for herd immunity; and interference by mater-
nally derived antibody (10, 11). Despite these problems, FMD 
vaccines can play a vital role in disease control and are very widely 
used, with over two billion doses estimated to be used globally 
each year (12). The general reasons for vaccination failure have 
been helpfully summarized by Heininger et  al. (13). “Vaccine 
failure” may be related to the recipient (pig) or the actual vaccine. 
“Failure to vaccinate” can be due to errors in vaccine use by the 
user and program-related problems. In the context of porcine 
FMD vaccines, these key issues are summarized in Figure 1.
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iMMUNiTY AND iMMUNOGeNiCiTY
Comparative interpretation of reports on the evaluation of FMD 
vaccines are often complicated by significant differences in the 
potency and other characteristics (e.g., different adjuvants and oil 
emulsions) of the different vaccines under study, as well as differ-
ent methods and severity of challenge models (mainly direct or 
indirect contact with infected unvaccinated or vaccinated donors 
or intramuscular or intradermal inoculation). The immune 
responses of pigs to FMD vaccines are less well studied than those 
of cattle (e.g., details of antibody isotypes, of local immunity, of 
breadth of antigenic protection, and of the correlation between 
antibody responses and protection), and there are few field study 
reports on vaccinated pigs (14). As for cattle and other species, 
establishing reliable correlates of serological protection for easy 
interpretation of field studies on vaccine-induced immunity in 
pigs are hampered by their dependence on specific attributes of 
the tests, vaccines, and challenge viruses involved.
immune Response to FMD  
vaccines in Pigs
Inactivated oil-adjuvanted FMD vaccines elicit antibody responses 
in pigs, and the extent of seroconversion measured by virus 
neutralization and liquid phase blocking ELISA (LPBE) tests can 
help to predict clinical protection (15–17). Eblé et al. (18) showed 
that reduced virus shedding was also correlated to neutralizing 
antibody levels induced by vaccination and that vaccine-induced 
mucosal IgA was associated with reduced susceptibility to 
infection. Cox et al. (19) showed that pigs immunized with high-
potency vaccines could be protected against challenge 7 months 
later, associated with sustained levels of neutralizing antibody and 
a sustained increase in some cytokine levels in serum (IL-6, IL-8, 
and in some pigs IL-12). Compared to unvaccinated pigs, vac-
cinated animals that became infected had lower and shorter lived 
antibody responses to FMDV non-structural proteins (18, 20).
High potency vaccines can protect pigs by ~4 days after vac-
cination, before the development of appreciable antibodies (21) 
and, as for cattle, there appears to be a gray zone where the protec-
tion afforded by low levels of antibody is unpredictable (17). This 
suggests that other factors are involved in protective immunity. 
Systemic levels of some cytokines have been shown to increase 
following FMD vaccination in pigs (22, 23), and Rigden et  al. 
(24) showed enhanced chemotaxis of cells of the innate immune 
defenses. Furthermore, the induction of both cellular and 
humoral arms of the immune system postvaccination has been 
demonstrated by measuring Th1 [interferon (IFN) gamma] and 
Th2 (IL-10) responses (25). Zhang et al. (17) studied cell-mediated 
immunity in 30 vaccinated and 3 unvaccinated pigs given three 
different doses of vaccine and challenged intramuscularly with 
1000 pig ID50 at 28 days post vaccination (dpv). Twenty-five pigs 
had antibody levels measured by LPBE that could be associated 
with protection or not (the gray zone). Protection was associated 
with vaccine-induced increases in cytotoxic T cell numbers and in 
levels of IFN gamma, IL-12, and IL-15 in serum. Garcia-Briones 
et al. (26) reported that a recombinant vaccinia virus expressing 
the FMDV 3D protein could partially protect pigs through a 
cell-mediated mechanism in the absence of a humoral antibody 
response to FMDV.
vACCiNe POTeNCY AND PROTeCTiON
Potency is defined by the OIE as the “concentration of the immu-
nologically active component” (27). Potency according to this 
definition is often measured by vaccine manufacturers through 
the quantification of antigen so that a dose of a vaccine delivers a 
known antigen “payload.” The conventional method of evaluating 
the effectiveness of FMD vaccines is by experimentally challeng-
ing vaccinated and unvaccinated control animals. Although 
inconsistent with the OIE definition of potency, these evalua-
tions are commonly known as “potency tests.” The first of these 
tests estimates the 50% protective dose (PD50) value and is also 
the recommended European Pharmacopeia (EP) test. The PD50 
value is defined as the dose that protects 50% of those under the 
particular challenge regimen (28). The second OIE-approved test 
is the “Protection against Podal Generalisation” (PPG) method, 
which is commonly used in South America.
In the 2009 OIE guidelines, there are descriptions of protocols 
for calculation of the PD50 and PPG based on challenge experi-
ments in pigs which are very similar to those described in cattle. 
For the PD50, three groups of five pigs, no younger than 2 months 
of age and free of FMD serum antibody, are given either a full 
dose, quarter dose, or 1/16th dose. They are challenged 28 days 
later by intradermal inoculation of 10,000 TCID50 of the vaccine 
strain into one of the heel bulbs of the foot. Two unvaccinated 
control pigs are included for comparison and to demonstrate a 
consistent phenotype of the challenge strain. For the PD50 test, the 
main difference with the pig protocol is the route of inoculation, 
as cattle are challenged via the intradermolingual route. A PPG 
equivalent, whereby 16 animals are challenged after receiving a 
full dose is also described. These descriptions were not included 
in the 2015 version of this document that states “In general, a 
successful test in cattle is considered to be sufficient evidence of 
the quality of a vaccine to endorse its use in other species. Under 
circumstances where a vaccine is produced for use primarily in a 
species other than cattle, it may be more appropriate to potency 
test the vaccine in that same species” (27). Li et al. (29) have pro-
posed an easier approach to inoculation by challenging intramus-
cularly behind the ear although a suckling mice passaged strain 
was needed over a conventional cell passaged version. In China, 
intramuscular inoculation of 1000 pig ID50 of challenge virus is 
widely used, as described in studies to evaluate novel vaccines 
(see section below).
Transmission Studies
There are numerous examples of challenge studies in pigs in 
the scientific literature to either evaluate the clinical protection 
afforded by vaccines or their potential role in reducing transmis-
sion. Salt et al. (21) evaluated a high potency, oil-based, monova-
lent serotype C vaccine (strain Oberbayern) by exposing groups 
of three non-vaccinated or vaccinated pigs to infected animals 
at 4, 8, 12, 16, and 21 dpv. The challenge virus was homologous 
to the vaccine strain. Contact was indirect to simulate airborne 
transmission and looked at both “water-in-oil-in-water” and 
4Lyons et al. Foot-and-Mouth Disease Vaccines in Pigs
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“oil-in-water” vaccines. All unvaccinated controls showed gen-
eralized disease, but all vaccinated animals were protected from 
clinical disease. Li et al. (29) reported the findings of a homolo-
gous PPG test for a serotype O strain using 16 vaccinated pigs and 
3 unvaccinated controls that were challenged intramuscularly 
behind the ear, 28  dpv. All vaccinated animals were protected 
from clinical disease, and the authors stated that two of the three 
controls had to show clinical disease for the test to be valid.
Eblé et al. (30) used challenge studies to estimate the impact of 
vaccination on transmission within pens in a high containment 
unit using a serotype O Taiwan strain. The vaccine was a double 
oil emulsion containing 3 μg of 146S antigen per dose. A single 
animal in a group of six was challenged by intradermal inoculation 
in the heel bulb, 7 or 14 dpv. Transmission to the in-contact pigs 
was evaluated by observing clinical signs, seroconversion to NSP 
antibodies, and detecting virus in oral swabs and serum. Three of 
the five contact animals in the 7-day group showed generalized 
clinical disease compared to none of those in the 14-day group. 
Additionally, no virus could be detected in the 14-day group 
providing evidence that vaccination can reduce transmission at 
14 dpv in this setting. In contrast, a study performed by Parida 
et al. (20), evaluated transmission and protection at 10 and 29 dpv. 
The oil-adjuvanted vaccine used was of high potency (>18PD50 
based on cattle experiments) and contained the O Manisa strain. 
Challenge was through exposure by direct contact with pigs with 
clinical disease caused by the O UKG 34/2001 strain of serotype 
O. Of animals challenged at 10 dpv, 13/16 (81%) were clinically 
diseased, while in the 29-day group, 2/8 (25%) were affected. In 
both groups, disease was reported to be milder and associated 
with reduced virus shedding compared to the unvaccinated con-
trol animals. Similar studies by Orsel et al. (31) aimed to assess 
transmission from infected, vaccinated pigs that had received 
O Manisa vaccine 14  days before challenge with O/NET/2001. 
They showed that vaccinated pigs could transmit infection to 
other vaccinated pigs as readily as to non-vaccinated controls. 
However, further work by the same group demonstrated that 
vaccination was able to reduce the transmission between pens 
(32). The differences reported in these studies could be attributed 
to different exposure methods, strains, or the small numbers of 
animals used.
Challenge studies were also performed to evaluate protec-
tion from an O Manisa vaccine to a strain from the O Mya98 
lineage (33). Vaccines were double oil adjuvanted and >6.0PD50 
(presumably based on bovine challenge studies although this is 
not stated). Groups of five pigs were vaccinated and intradermally 
challenged at either 4 or 7 dpv. A non-vaccinated control group of 
five animals was also challenged for comparison. All control ani-
mals showed generalized disease. Four out of five (80%) animals 
challenged at 7 dpv were protected compared with three (60%) 
animals challenged at 4 dpv indicating animals may be protected 
soon after vaccination. Virus shedding was significantly lower 
in vaccinated animals compared to controls. Each group was 
in indirect contact (not physical but shared air handling unit) 
with five unvaccinated pigs to assess transmission in a controlled 
environment. No clinical signs or seroconversion was seen in pigs 
that were in contact with the vaccinated groups despite live virus 
being detected in the blood. This is in contrast to pigs that were in 
contact with the unvaccinated control animals although a breach 
in biosecurity may have explained this contrast. A similar study 
was performed by the same group using a serotype A Malaysia 97 
vaccine and a serotype A/ASIA/Sea-97 lineage challenge strain 
(relationship value, r1, around 0.5). Protection from generalized 
clinical disease was seen in all animals vaccinated 4 and 7 days 
pre challenge. No disease, FMD antibodies, or live virus was seen 
in the contact groups, although some animals in contact with the 
4-day group were PCR positive on nasal swab (34).
In response to an FMD epidemic in Southeast Asia where there 
was only a moderate match between field and O Manisa vaccine 
strains (r1 around 0.3), Park et al. (35) performed homologous 
and heterologous challenge studies to evaluate a new vaccine seed 
strain (O/Andon/SKR/2010). Groups of five, FMD antibody-free, 
3-month-old pigs received one of three different antigen payloads 
(7.5, 10, and 15 μg) in an oil-adjuvanted vaccine and were intra-
dermally challenged 30  dpv with the homologous O/Andon/
SKR/2010 strain. Two placebo injected pigs were challenged for 
comparison. All vaccinated animals were protected from clinical 
disease, ignoring any lesions seen at the inoculation site. Both 
control animals had generalized disease. The 10 μg group was 
subsequently challenged with a heterologous strain of the ME-SA 
topotype (r1 value around 0.5), and all animals were protected 
from clinical disease.
Challenge studies like those described can provide useful 
information on the potential role of vaccines in FMD control. 
There is evidence that protection may occur as early as 4 days, and 
vaccination may reduce transmission. Great care must be taken 
when extrapolating such results to a population level due to several 
factors including: variability in effective contact rates and virus 
shedding (quantity and duration) in the field; exposure routes 
and doses that have unclear relevance to field conditions; small 
sample sizes leading to uncertainty in the results from random 
error; and likely reduced responses to vaccination under program 
conditions. Therefore, these studies should be complimented by 
field-based epidemiological studies. Nowadays, decision making 
on how and when to use vaccination is greatly influenced by 
simulation studies with computer models. Unfortunately, it is 
not yet clear how to parameterize such models to make use of the 
results of potency tests.
vACCiNATiON PROGRAMMeS
The level of immunity required to control disease at a population 
level depends in large part on the basic reproduction number (R0) 
defined as the average number of secondary cases for each pri-
mary case in a completely susceptible population. The “effective” 
reproduction number is the same calculation but in a population 
with a proportion of immune individuals. If the effective repro-
duction number is less than one, on average, the circulation of 
infection will tend to reduce and ultimately cease. On this basis, 
the herd immunity required to bring the reproduction number 
to this level (called the “herd immunity threshold” or HIT) can 
be calculated by
 
HIT = −1 1
0R  






Once at 2.5 mo (if sporadic FMD cases in area) “Guidance for Foot and Mouth 
Disease Vaccination,” Merial 
Animal Health Limited
Twice at 2 and 3 mo (Epizootics or highly virulent strain)
>2 wo if unvaccinated herd
DECIVAC (MSD 
Animal Health)






Young animals with maternal antibodies: primary dose 4–8 wo onward, second dose 6 weeks later in endemic 
areas, with revaccination 4–6 months later
Adults: every 6 months
Based on manufacturers listed at http://www.cfsph.iastate.edu/Vaccines/ (accessed August 9, 2016), where the company website states the schedule in English language and 
specifically for pigs. Both vaccines are licensed for intramuscular injection in the neck region.
wo, weeks old; mo, months old.
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The basic reproduction number depends on the effective 
contact rate (i.e., contact between individuals sufficient for 
transmission per unit time, also known as the transmission 
parameter), duration of infectiousness, and population size (36). 
It is possible to estimate the duration of infectiousness from 
transmission studies although there is likely variation between 
viral strains and hosts (37). The effective contact rate is likely to 
be variable depending on environmental factors such as popula-
tion or stocking density, production systems, season, and nature 
of any biosecurity practices. There is also the added complexity 
of population structures and the consideration of transmission 
at both the within and between herd level (38). R0 and the HIT 
can be estimated using mathematical models, although these 
should be parameterized as much as possible from field data and 
tailored to a specific country or region. Small-scale transmission 
studies can be used to parameterize models, but these should be 
validated from field-derived data to give greater confidence in 
model predictions.
The HIT is useful in giving a theoretical target for vaccination 
coverage (39). In pigs, maintaining sufficient population immu-
nity through vaccination for FMD is a major challenge. Virus 
transmissibility is potentially high due to higher levels of virus 
excretion in this species (40), the intensive nature of modern pig 
production, and a rapid population turnover (particularly in fat-
tening pigs typically slaughtered at 6–7 months old). Additionally, 
maternal antibodies interfere with the response to vaccines, and 
there is need for repeated doses of vaccine (discussed in detail 
in the following section). In some sub-populations with a high 
transmission risk, a relatively higher vaccination coverage is 
likely to be required making the case for risk-based vaccination 
targeting areas of high transmission identified using repeatable 
epidemiological methods.
vaccination Regimes
Table 1 gives two proposed schedules for FMD vaccination in pigs 
both of which acknowledge the potential impact of maternally 
derived antibodies (MDA). Experiments have tried to address the 
issue of MDA interference with vaccination. Francis and Black 
(41) found that pigs as young as 1 week of age could mount a 
neutralizing antibody response to vaccine in the absence of 
MDA. They compared these responses to piglets with MDA from 
vaccinated sows and found that piglets aged between 1–4 weeks 
did not show any response with antibodies continuing to decline. 
An increase was seen in piglets vaccinated at 8 weeks old but was 
lower in the presence of higher levels of MDA. A recent study by 
Dekker et al. (42) assessed the serological response to vaccination 
in piglets at different ages (3–9 weeks) in the presence of MDA. 
Based on receiving a single dose and neutralizing titers 6 weeks 
post vaccination, the authors found that vaccination at 7–9 weeks 
old was optimal. Increases in titers were seen in all age categories 
although the responses were heavily dependent on the MDA 
level, which in turn was heavily influenced by the titer in the sow.
Two published studies from Taiwan have attempted to estab-
lish the optimal times and schedules for vaccination in pigs using 
field-derived serological evidence. Chung et al. (43) performed 
serological surveys as part of an active surveillance strategy on 
commercial pig farms with a herd size ≥5000. Farms were using 
an oil-based, >6.0PD50 serotype O vaccine. Two dose primary 
course schedules of 8 and 12  weeks, 10 and 14  weeks, and 12 
and 16 weeks were compared through homologous neutralization 
tests on sera from 97 farms. This suggested that animals vacci-
nated at 12 and 16 weeks of age had the highest titers and there 
were significant differences between the vaccine products. This 
analysis was univariable and did not account for possible con-
founders and the time between vaccination and sampling. Liao 
et al. (44) performed a study whereby groups of between 6 and 15 
piglets were vaccinated between 2 and 16 weeks old (some groups 
receiving a booster 4  weeks later). Based on neutralizing titers 
and homologous challenge studies, both performed at 24 weeks 
old, the authors suggested the optimum time for the first dose 
to be 8 weeks of age and titers were not significantly different if 
the piglet received a second dose at 12 weeks of age. This latter 
evidence for not needing a second dose based on antibody titers 
is contrary to the suggested schedules in Table 1.
Routes of Administration
Both of the vaccines listed in Table 1 are licensed for intramus-
cular administration in the neck region. Granulomas have been 
reported to occur in pigs at injection sites post vaccination with 
water-in-oil adjuvants (45). Although according to McKercher 
and Gailiunas (45) these were barely visible 6–12 months after 
vaccination, this could still be a problem in fattening pigs 
FiGURe 2 | Gross pathology lesion of an injection-site granuloma in 
the neck region of a pig from the Republic of Korea.
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slaughtered at 6–7  months of age where the neck region can 
have significant value. Such lesions have been reported to occur 
in 15–20% of pigs but could be easily removed by dissection at 
slaughter (46). Basarab et al. (47) reported 5/32 (16%) pig car-
cases had large residual lesions after using a water-in-oil emulsion 
FMD vaccine requiring extensive dissection. These animals were 
vaccinated as weaners and the lesions were present at the end of 
the fattening period although the exact length of time between 
vaccination and slaughter is not reported. This same study 
found that intraperitoneal vaccination was equally efficacious to 
pigs vaccinated intramuscularly based on challenge studies but 
without the local tissue reaction. An experimental study by Eblé 
et al. (48) demonstrated that intradermal vaccination at 1/10th 
the dose of a normal killed vaccine was equally as effective based 
on challenge studies and neutralizing titers. The small numbers of 
animals in both of these studies may mean they were statistically 
underpowered, although both intraperitoneal and intradermal 
vaccination may offer significant advantages by reducing tissue 
lesions in fattening animals.
The issue of injection-site granulomas post vaccination has 
been particularly highlighted in the Republic of Korea and has 
been proposed as an important factor that has contributed to a 
reduced uptake of vaccination that has compromised coverage. As 
an example, a recent unpublished survey of 470 fattening cross-
bred pigs from four commercial farms found visually observable 
lesions in 87, 80, and 80% at 1, 2, and 3 months post vaccination, 
respectively. These were visible in live pigs, and all had received a 
two-dose primary course with the first dose given at 6–8 weeks of 
age and the second dose 2 weeks later. The injection site was in the 
neck approximately 2.5 cm caudal to the base of the ear. A subset 
of animals were slaughtered to demonstrate the gross pathology 
present as shown in Figure 2.
Although maintaining effective levels of coverage are 
challenging, a good understanding of the epidemiology will 
inform targeted vaccination strategies and more effective use of 
resources. The optimal vaccination schedules will vary depending 
on the antibody levels in the sow, which in turn will depend on 
vaccine type and schedules, natural exposure, and other sow- or 
piglet-related factors. Therefore, it is clear that countries embark-
ing on vaccination programs should perform their own studies 
to establish optimal vaccination strategies as also suggested by 
Dekker et al. (42).
NOveL APPROACHeS TO vACCiNeS AND 
vACCiNATiON
Recent years have seen encouraging results with novel FMD 
vaccines and adjuvants. Those tested in pigs are considered 
briefly in this review and Table 2 summarizes some of the most 
promising challenge studies. Peptide vaccines for type O FMDV 
have been used in China for vaccination of pigs and continue 
to be improved. More data are needed on the breadth of cross-
protection afforded by these vaccines against heterologous virus 
strains of the same serotype as used for peptide design. New 
vaccines have been designed, modified, and evaluated based 
upon FMD virus-like particles (VLP) generated in vitro or in the 
vaccinated pig through expression by virus vectors, especially 
adenoviruses. Specific methods of attenuating live FMDV now 
show considerable promise for overcoming the problem of com-
bining inocuity with immunogenicity and can provide protection 
within 2 days. Data on duration of protection are awaited. IFNs 
and IFN inducers can not only provide extremely rapid and 
serotype non-specific protection against FMDV but they can also 
enhance the protection afforded by specific FMDV antigens and 
reduce the doses of adenovirus-vectored vaccines required for 
protection. New adjuvants have mostly been tested as additional 
incipients for oil-based vaccines and properly controlled and 
powered comparative studies of different adjuvants have not been 
published. There have been few recent studies of mucosal vaccine 
targeting or to evaluate DNA vaccines.
Adenovirus-vectored vaccines
Adenovirus-vectored FMD vaccines conditionally licensed 
in the USA in 2012 for use in cattle, have also shown efficacy 
in pigs. A replication-defective human serotype 5 adenovirus 
expressing the capsid encoding genes and the 3C protease 
needed for their cleavage and incorporating genetic material 
from the A24 strain of FMDV was given to pigs at a dose of 
5 ×  109  pfu, resulting in complete clinical protection against 
homologous FMDV by contact challenge at 7, 14, and 42 dpv 
(56). It was later shown that a modified vector insert also 
expressing the FMDV 2B gene improved the early antibody 
response to the FMDV capsid (57).
The same adenovirus vector when administered at high doses 
can deliver IFNs to provide early protection against FMDV and 
types I, II, and III IFN given this way can all provide protection to 
pigs for up to 5 days with evidence of synergistic action between 
different IFN types [reviewed by Stenfeldt et  al. (58)]. Patch 
et al. (59) explored the possibility of selecting for a cytotoxic T 
cell response to FMDV in pigs vaccinated with an adenovirus 
expressing an inefficiently cleaved capsid precursor, but the 
protective value of this was not reported.
TAbLe 2 | Selected pig challenge study results with promising outcomes for novel vaccines.
vaccine vaccinationa Challenge Protection Reference
Live FMDV A12 attenuated by 
Lpro mutation (A12-SAP)
15 pigs vaccinated with 105, 106, or 
107 pfu A12-SAP by subcutaneous 
injection
Intradermal heel bulb inoculation 
with 105 FMDV A12 at 21 dpv
All 15 pigs protected against clinical 
signs (fever or vesicles), viremia, and 
nasal shedding
(49)
9 pigs vaccinated with 106 pfu A12-SAP 
by subcutaneous injection
Intradermal heel bulb inoculation 
with 5 × 105 FMDV A12 at 2, 7, 
or 14 dpv
8 of 9 pigs protected against clinical 
signs
Adenovirus vector expressing 
FMDV A24 P1-2A, 2B, 3B, 3C 
with Poly ICLC adjuvant in PBS
6 pigs vaccinated with 2.5 × 106 vector 
plus 1 mg poly ICLC by subcutaneous 
injection of 2 ml dose at 2 sites (other 
vaccination schedules evaluated)
Intradermal heel bulb inoculation 
with 105 FMDV A24 at 7 or 21 dpv
All 3 pigs challenged at 21 dpv 
protected against clinical signs, 
viremia, and nasal shedding (partial 
protection when challenged at 7 dpv)
(50)
Adenovirus vectors, one 
expressing porcine alpha and 
gamma interferons and the other 
expressing 3 small interfering 
RNAs
15 minipigs vaccinated with 7.2 × 109 or 
1.75 1010 TCID50 of a combination of the 
adenovirus vectors (1:5 ratio of Ad-IFN 
titer to Ad-3siRNA titer) by intramuscular 
injection (other vaccination schedules 
evaluated)
Direct contact of 5 groups of 3 
“vaccinated” minipigs at 2, 4, and 
7 dpv, for 18 h with donor minipigs 
infected with FMDV strain O/
Andong/SKR/2010
At the low “vaccine” dose, complete 
clinical protection in 2/3, 1/3, and 
0/3 minipigs at 2, 4, and 7 dpv. At 
the high “vaccine” dose it was 3/3 
and 1/3 at 4 and 7 dpv. Viremia 
and oral shedding also reduced or 
prevented in some minipigs
(51)
FMDV multi-epitope (B and 
T cell) from 4 FMDV O topotype 
viruses with poly IC adjuvant. 
VP1 epitopes from O/Mya/98, 
O/HN/CHA/09, O/Tibet/99, O/
IRN/2010. Two universal (non-
FMDV) T cell epitopes
45 pigs vaccinated in three groups of 
15 pigs, each group consisting of 3 
subgroups of 5 pigs receiving different 
doses: full (2 ml), 1/3, or 1/9 dose by 
volume intramuscularly. The full dose 
contained 300 μg of epitope protein and 
300 μg poly IC
Three potency tests involving 
challenge at 28 dpv by 
intramuscular inoculation with 
1000 50% infectious doses of 
one of three FMDV O strains: 
O/Mya/98, O/HN/CHA/93, O/
Tibet/99
PD50 results were 15.6 (O/Mya/98 
challenge), 15.6 (O/HN/CHA/93), 
and 7.0 (O/Tibet/99)
(52)
Pseudorabies virus expressing 
P1-2A, 3C from FMDV O/
ES/2001 (PRV-P12A3C)
5 pigs vaccinated with 106 TCID50 
PRV-P12A3C in 2 ml by intramuscular 
injection with identical booster at 21 dpv
1000 50% infectious doses of 
FMDV O/OR/80 by intramuscular 
inoculation at 15 days after 
booster vaccination




VLP produced in E coli as 
SUMO-VP0/VP1/VP3 fusion 
proteins, subsequently purified 
and cleaved
5 pigs vaccinated with 50 μg VLP in oil 
adjuvant by intramuscular route
1000 50% infectious doses of 
FMDV Asia1/Jiangsu/China/2005 
by intramuscular inoculation
All 5 vaccinated pigs fully protected 
against clinical signs
(54)
Dendrimeric B and T cell 
epitopes from FMDV O/
UKG/11/2001
6 pigs vaccinated twice 21 days apart 
with 2 ml oil adjuvant containing 2 mg 
peptide by intramuscular route (other 
related vaccines evaluated)
1.6 × 104 FMDV O/UKG/11/2001 
by heel bulb inoculation at 18 days 
after second vaccination
All 6 vaccinated pigs fully protected 
against clinical signs and for 5 of 6 
pigs no virus shedding detected in 
pharyngeal or nasal swabs
(55)
aAll studies included control mock or unvaccinated pigs, and some studies included comparison with conventional vaccines, but details not given here.
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Kim et al. (51) developed recombinant adenoviruses for the 
simultaneous expression of porcine alpha and gamma IFNs as 
well as three small interfering RNAs targeting FMDV mRNAs 
encoding non-structural proteins. The antiviral effects of these 
vectors were synergistic in porcine cells, suckling mice, and 
minipigs. The vectors administered at high dose by the intramus-
cular route fully protected 3 pigs against an 18-h direct contact 
challenge 1 day later. Partial protection at challenge 2–4 days after 
administration was mostly lost at 7 days. In vitro, the combination 
treatment was effective against all serotypes of FMDV.
Other vectored vaccines
Canine adenovirus type 2 expressing VP1 elicited low levels 
of FMDV neutralizing antibody in pigs (60). A recombinant 
pseudorabies virus expressing the capsid and 3C encoding genes 
of FMDV serotype O partially protected (3 of 5) pigs against an 
intramuscular challenge with 1000 ID50 of a heterologous live 
type O FMDV [(53); Table 2]. An earlier pseudorabies virus vec-
tor expressing only VP1 of FMDV was less effective (61).
Yang et  al. (62) reported the insertion of VP1 T and B cell 
epitopes of FMDV serotype O into a bamboo mosaic virus 
(BMV), resulting in expression of a fusion protein. Pigs inocu-
lated intramuscularly with 5–10  mg of the recombinant BMV 
in a mineral oil adjuvant produced VP1-specific cell-mediated 
immunity and neutralizing antibodies. The protection of pigs 
against challenge with live FMDV was described after a double 
dose of the recombinant BMV, and protection was said to be 
possible after one dose.
Recombinant baculoviruses were used by Crisci et al. (63) to 
generate chimeric virus-like particles of rabbit haemmorhagic 
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disease virus fused to a FMDV T cell epitope from the 3A viral 
non-structural protein. Intramuscular inoculation of pigs with 
this chimera and an oil adjuvant generated FMDV-specific cell-
mediated immunity and antibodies.
interferons
Polyriboinosinic-polyribocytidylic acid stabilized with poly-
l-lysine and carboxymethyl cellulose (poly ICLC) is a synthetic 
double-stranded RNA (dsRNA) that is a viral mimic and activates 
multiple innate immune pathways through interaction with 
toll-like receptor 3 and MDA-5. It is a potent inducer of IFNs 
and can protect against FMD at 1  day after treatment (64). Its 
adjuvant affect on FMD vaccines in pigs was reported 40 years 
ago (65). Recently, it was shown to reduce, by 80-fold, the dose 
required for protection of a recombinant adenovirus expressing 
FMDV A24 capsids [(50); Table 2]. Another synthetic analog of 
dsRNA, polyinosinic-polycytidylic acid (poly IC), potentiated the 
protection afforded by a multi-epitope vaccine in pigs (66). This 
vaccine incorporated linked B cell epitopes (the G–H loop and C 
terminus of VP1) from four topotypes of serotype O flanked by 
two universal T cell epitopes. The final product in an oil adjuvant 
with poly IC protected pigs with 50% protection values of 7–16 
against different challenge viruses [(52); Table 2].
Other Adjuvants
Barrette et al. (67) showed that intranasal immunization of pigs 
with detoxified Escherichia coli enterotoxins LTK63 and LTR72 
linked to a peptide derived from the FMDV serotype O1-BFS 
VP1 G-H loop enhanced the antigen-specific mucosal and sys-
temic immune responses to FMDV. Guo et al. (68) reported that 
a CpG-enriched plasmid enhanced the efficacy of a conventional 
FMD killed vaccine. Park et al. (35, 69) vaccinated groups of five 
pigs with a conventional FMD vaccine antigen plus either the oil 
adjuvant used in the Republic of Korea or with novel adjuvants 
(Carbigen, Emulsigen-D and ISA 201). In terms of immune 
response and post-challenge protection, the novel antigens were 
at least as good.
In a small field trial, administering 60  mg of poly gamma 
glutamic acid (PGA) 3 days before FMDV vaccination of young 
pigs resulted in slightly more animals with detectable levels of 
FMDV antibodies 2–6  weeks later (70). Li et  al. (71) reported 
increased antibody responses of pigs to a conventional FMDV 
vaccine supplemented with ginseng stem and leaf saponins. 
Xiao et al. (72) showed that an extract of the seeds of Momordica 
cochinchinensis (Lour.) Spreng. (ECMS) had a synergistic effect 
in improving the immune response of pigs after vaccination with 
inactivated FMDV antigens in an oil emulsion vaccine.
Live Attenuated vaccines
Deleting the Lpro gene of FMDV A12 gave rise to an attenuated 
virus that partially protected pigs against wild-type challenge (73). 
Meanwhile, FMDV A24 lacking Lpro but with a capsid substituted 
from serotype O was still somewhat virulent for pigs. Changing 
the capsid genes to those of a cell culture adapted virus eliminated 
the virulence, but the resulting virus did not protect pigs when 
used as a vaccine (74). In contrast, mutating a conserved protein 
domain within the Lpro gene of FMDV A12 gave rise to a virus 
that was avirulent in pigs at a dose of 107 but nevertheless elicited 
protection against FMDV challenge from 2 dpv (49).
Codon bias deoptimization of the FMDV capsid-coding region 
(P1) introduced 489 nucleotide changes (19%) but retained virus 
viability. The vaccine safety margin was ~1000-fold higher for 
pigs than for wild-type virus. Consistently, high levels of antibody 
titers were induced, even at the lowest dose tested (75).
Protein/Peptide vaccines
Shao et al. (76) reported on the further development of a tandem 
repeat multiple-epitope recombinant vaccine against FMDV 
serotype O containing three copies of two VP1 epitopes of 
the O/China/99 strain of FMDV coupled with a porcine IgG 
heavy-chain constant region (77). This peptide vaccine elicited 
high titers of FMDV specific antibodies in pigs at 30  dpv and 
conferred complete protection against a challenge with 1000 50% 
infective doses of the O/China/99 strain. Trials of another B cell 
epitope vaccine (52) have already been described above under 
IFNs (Table 2). Dong et al. (78) inserted the coding sequences 
of a FMDV serotype O VP1 epitope into a coliphage, resulting in 
an epitope-phage recombinant protein that formed a virus-like 
particle (VLP). Challenge inoculation of twice vaccinated pigs 
with the live homologous virus resulted in three of five animals 
being clinically protected from FMD.
Building upon earlier work (79, 80), Blanco et al. (55) reported 
that a synthetic dendrimeric peptide vaccine comprising two 
copies of a FMDV VP1 B cell epitope linked to a FMDV 3A T cell 
epitope protected pigs against disease and virus shedding after 
two doses of vaccination followed by challenge inoculation with 
live homologous FMDV O UK 2001 (Table 2). Guo et al. (54) 
have developed a bacterial expression system to generate VLPs of 
the FMDV Asia 1 capsid proteins. The FMDV genes VP0, VP1, 
and VP3 were each expressed as fusion products with the small 
ubiquitin like modifier protein (SUMO) and after removal of the 
SUMO moiety, the FMDV proteins assembled into VLPs. Five 
pigs vaccinated with 50 μg of VLP emulsified in oil adjuvant were 
fully protected from challenge inoculation with live homologous 
FMDV (Table 2).
DNA vaccines
DNA vaccines have not been completely effective in livestock 
despite promising results in mice. Multiple doses of plasmids 
expressing FMDV proteins or epitopes with coexpression of 
immunostimulants, and/or with conventional antigen boosters 
have been required to protect pigs against FMD (81–83). Most 
recently, Borrego et  al. (84) reported partial protection of pigs 
after three immunizations with a DNA vaccine encoding FMDV 
B and T cell epitopes fused to the variable fragment of a mouse 
immunoglobulin against Class II swine leukocyte antigens.
Mucosal vaccines
Although mucosal IgA may be elicited by parenteral immunization 
routes [e.g., Ref. (80)], mucosal vaccination might help to block 
FMDV entry. Barrette et al. (67) evaluated detoxified Escherichia 
coli enterotoxins LTK63 and LTR72 as mucosal adjuvants show-
ing enhanced antigen-specific mucosal and systemic immunity 
for non-replicating antigens, including FMDV, upon intranasal 
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immunization in pigs. Song et  al. (85) reported vaccination of 
pigs with a recombinant VP1 epitope complex of serotype O 
FMDV fused to the cholera toxin B subunit (hCTB). Eight of ten 
pigs that were given three intraperitoneal immunizations were 
protected from challenge by inoculation with 106.5 TCID50 type 
O FMDV. Wang et  al. (86) showed that intranasal delivery of 
cationic PLGA nano/microparticles loaded with various FMDV 
DNA vaccine formulations encoding IL-6 as a molecular adju-
vant enhanced protective immunity against FMDV, particularly 
pc-IL2AP12A3C with the IL-6 gene located before the P12A3C 
gene. Nevertheless, only partial protection against challenge with 
FMDV was achieved in pigs.
Chimeric Killed vaccines
Blignaut et  al. (87) produced a killed vaccine from a chimeric 
virus in which the capsid encoding genes were replaced with 
those from a different serotype. The resulting SAT 2 FMDV with 
a SAT 1 capsid were used to make a conventional killed vaccine 
that was potency tested in 17 pigs (three groups of five pigs given 
different vaccine doses and two unvaccinated control pigs). After 
a SAT 1 challenge by heel bulb inoculation, the PD50 was found 
to be >6.4. Zheng et  al. (88) substituted the capsid-encoding 
region of a serotype A virus vaccine for a more recent field isolate 
to update the antigenic match. The new vaccine was shown to 
protect against both the homologous strain and another semi-
heterologous one.
ReSeARCH PRiORiTieS
This review summarizes studies that have been undertaken to 
evaluate the performance of FMD vaccines in pigs, as well as 
introduce novel vaccination strategies that might be employed 
for FMD control in the future. Collectively, these data provide a 
valuable body of evidence that are especially relevant in the parts 
of the world where pigs play a central role in the maintenance and 
spread of the virus. Although a number of these experimental 
studies have evaluated the performance of FMDV vaccines, it is 
apparent that field data for such evaluation in pigs are currently 
lacking. Furthermore, much of this work is dependent upon 
bovine reagents, such as antigenic profiling (vaccine-matching), 
or exploits in  vitro measurements of “correlates of protection” 
derived from cattle studies. In view of this paucity of data, when 
using vaccines in these settings, it is important to consider the 
different factors that influence whether, or not, a vaccine is likely 
to be efficacious. These include the (i) regime used (timing and 
frequency of vaccination); (ii) potency and formulation of oil 
vaccines; and (iii) antigenic match between the vaccine and circu-
lating field strain. Although these three points are often assessed 
(and discussed) separately, they have an intimate relationship that 
underpins the performance of a vaccine. For example, it is usually 
accepted that a less than perfect antigenic match can be com-
pensated by administration of a high potency vaccine; however, 
the impact of vaccine regime (as well as the herd-level coverage) 
is often ignored. In order to improve vaccine-induced immune 
responses, additional areas that warrant further scientific inves-
tigation include more systematic research to evaluate alternative 
vaccine adjuvants for vaccination in pigs, and research to validate 
of alternative routes (IM, IP, SC, ID) and sites of vaccination (to 
minimize local tissue granulomas in valuable meat cuts) and even 
multiple sites (with a divided dose). Effective (improved) vaccina-
tion regimes are also necessary to generate optimum protection 
in pigs to accommodate maternal antibody responses (to reduce 
the immunity gap).
Data from recent field outbreaks in Asia highlight the chal-
lenges posed by the control of FMD in pigs. While initiatives to 
improve the quality of vaccines and coverage that are tailored 
for pigs have the potential to make a positive impact on FMD 
control, it should be remembered that vaccination-alone is not 
a magic panacea and that FMD control, especially in the face of 
high amounts of circulating virus, is often reliant upon the imple-
mentation of effective zoo-sanitary (bio-containment) measures, 
as well as the maintenance of adequate local veterinary resources 
so that new clinical cases are rapidly investigated and detected.
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